SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

HC Wainwright Maintains Genmab Buy, Raises Price Target to $70

HC Wainwright maintained its Buy rating on Genmab and raised its price target to $70 from $50.

GMAB

Related stories